Giampietri and colleagues found that OX40 was significantly upregulated in 36 cholangiocarcinoma samples compared to 9 normal control samples, suggesting that OX40 may play a potential role in cholangiocarcinoma, as both a diagnostic or prognostic marker and a therapeutic target (174). This evidence concerns the gene TNFRSF4 and cholangiocarcinoma.